- Conditions
- Multiple Myeloma
- Interventions
- TNB-383B
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 10
- States / cities
- San Francisco, California • New Orleans, Louisiana • Rochester, Minnesota + 6 more
Condition Directory
Multiple Myeloma clinical trials
Directory of U.S. ClinicalTrials.gov public records for Multiple Myeloma. Browse Multiple Myeloma recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 1, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
2318
Shown on this page
12
Current sort
Recently updated
Condition scope
Multiple Myeloma
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Multiple Myeloma studies are organized in the registry
Myeloma listings distinguish newly diagnosed from relapsed/refractory disease in their titles, and precursor conditions — smoldering myeloma and MGUS — are usually registered as separate condition terms. Cell-based and antibody platforms (CAR-T, bispecific antibodies) appear by name in many current titles.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 577–588 of 2,318 matching trials for Multiple Myeloma.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Interventions
- 18-NaF PET, DCE-MRI, 18-FDG PET/CT
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non-Hodgkin Lymphoma, Multiple Myeloma, Histiocytic Neoplasms, Erdheim-Chester Disease, Rosai-Dorfman Disease
- Interventions
- [68Ga]-Pentixafor
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lymphoma, Myeloma, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity Syndrome
- Interventions
- Home Automated Telemanagement (HAT) Patient Unit
- Device
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Multiple Myeloma
- Interventions
- Velcade, Thalidomide, Dexamethasone, Adriamycin, Cisplatin, Cyclophosphamide, Etoposide
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2027
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Multiple Myeloma
- Interventions
- Cevostamab, Tocilizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 6 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- Biospecimen Collection, Comprehensive Geriatric Assessment, Electronic Health Record Review, Survey Administration
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Multiple Myeloma
- Interventions
- Modakafusp Alfa, Daratumumab
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 13
- States / cities
- Gilbert, Arizona • Los Angeles, California • Fort Wayne, Indiana + 10 more
- Conditions
- Multiple Myeloma
- Interventions
- Modakafusp alfa, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 14
- States / cities
- Sacramento, California • San Diego, California • Iowa City, Iowa + 8 more
- Conditions
- Multiple Myeloma
- Interventions
- Modakafusp alfa, Dexamethasone
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 27
- States / cities
- Springdale, Arkansas • Glendale, California • Orange, California + 23 more
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib, Isatuximab, Cyclophosphamide, Dexamethasone
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Hematological Malignancy, Multiple Myeloma
- Interventions
- Evomela, Fludarabine, Total Body Irradiation, Haploidentical Hematopoietic Cell Transplantation
- Drug · Radiation · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
About this Multiple Myeloma clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Multiple Myeloma as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Multiple Myeloma.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Multiple Myeloma.